参考文献
[1]A. Velo-Garcia, S.G. Castro, D.A. Isenberg, The diagnosis and management of the haematologic manifestations of lupus, J. Autoimmun. 74 (2016) 139–160.
[2]P.T. Costa, R. Caparros-Ruiz, P. Gaspar, D.A. Isenberg, Prevalence and outcome of thrombocytopenia in systemic lupus erythematous: single-centre cohort analysis,Clin. Exp. Rheumatol. 39 (2021) 601–605.
[3] A. Fanouriakis, G. Bertsias, D.T. Boumpas, Population-based studies in systemic lupus erythematosus: immune thrombocytopenic purpura or ’blood-dominant’ lupus? Ann. Rheum. Dis. 79 (2020) 683–684.
[4] I.S. Hitchcock, M. Hafer, V. Sangkhae, J.A. Tucker, The thrombopoietin receptor:revisiting the master regulator of platelet production, Platelets 32 (2021),770–778.
[6] R. Li, K.M. Hoffmeister, H. Falet, Glycans and the platelet life cycle, Platelets 27 (2016) 505–511.
[9] L. Zhao, Y. Ye, X. Zhang, B cells biology in systemic lupus erythematosus-from bench to bedside, Sci. China Life Sci. 58 (2015) 1111–1125.
[12] M.V. Jonsson, P. Szodoray, S. Jellestad, R. Jonsson, K. Skarstein, Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren’s syndrome, J. Clin. Immunol. 25 (2005) 189–201.
[13] J.R. Vrbensky, D.M. Arnold, J.G. Kelton, J.W. Smith, A.M. Jaffer, M. Larche, et al.,Increased cytotoxic potential of CD8(+) T cells in immune thrombocytopenia, Br.J. Haematol. 188 (2020) e72–e76.
[14] L.M. Chapman, A.A. Aggrey, D.J. Field, K. Srivastava, S. Ture, K. Yui, et al.,Platelets present antigen in the context of MHC class I, J. Immunol. 189 (2012),916–923.
[16] J. Qiu, X. Liu, X. Li, X. Zhang, P. Han, H. Zhou, et al., CD8(+) T cells induce platelet clearance in the liver via platelet desialylation in immune thrombocytopenia, Sci. Rep. 6 (2016), 27445。
[17]T. Wang, H. Zhao, H. Ren, J. Guo, M. Xu, R. Yang, et al., Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura, Haematologica 90 (2005),914–923.
[18] S. Audia, M. Rossato, K. Santegoets, S. Spijkers, C. Wichers, C. Bekker, et al.,Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytopenia, Blood 124 (2014),2858–2866.
[20] M.M. Lee-Sundlov, L. Rivadeneyra, H. Falet, K.M. Hoffmeister, Sialic acid and platelet count regulation: implications in immune thrombocytopenia, Res Pract Thromb Haemost 6 (2022), e12691.
[21] P.M. Baroni, P.R. Lev, A.C. Glembotsky, O.C. Marin, G. Gomez, V. Collado, et al.,Pathogenic mechanisms contributing to thrombocytopenia in patients with systemic lupus erythematosus, Platelets 33 (2022) 743–754.
[22] S.S. Zheng, Z. Ahmadi, H. Leung, R. Wong, F. Yan, J.S. Perdomo, et al.,Antiplatelet antibody predicts platelet desialylation and apoptosis in immune thrombocytopenia, Haematologica (2022), 35199503.
[24] M. Roussotte, M. Gerfaud-Valentin, A. Hot, S. Audia, B. Bonnotte, T. Thibault, et al., Immune Thrombocytopenia with Clinical Significance in Systemic Lupus Erythematosus: A Retrospective Cohort Study of 90 Patients, Rheumatology,Oxford, 2021.
[25] R. Kado, W.J. Mccune, Treatment of primary and secondary immune thrombocytopenia, Curr. Opin. Rheumatol. 31 (2019) 213–222.
[26] F. Sun, J. Chen, W. Wu, S. Geng, W. Xu, S. Sun, et al., Rituximab or cyclosporin in refractory immune thrombocytopenia secondary to connective tissue diseases: a real-world observational retrospective study, Clin. Rheumatol. 39 (2020),3099–3104.
[28] D. Provan, D.M. Arnold, J.B. Bussel, B.H. Chong, N. Cooper, T. Gernsheimer, et al., Updated international consensus report on the investigation and management of primary immune thrombocytopenia, Blood Adv 3 (2019) 3780–3817.
[29]J.C. Santacruz, M.J. Mantilla, I. Rueda, S. Pulido, G. Rodriguez-Salas, J. Londono,A practical perspective of the hematologic manifestations of systemic lupus erythematosus, Cureus 14 (2022), e22938.
[30] B. Mayer, F. Depre, F. Ringel, A. Salama, New aspects on the efficacy of high-dose intravenous immunoglobulins in patients with autoimmune thrombocytopenia,Vox Sang. 112 (2017) 64–69.
[34] Y. Dong, M. Yue, M. Hu, The efficacy and safety of different dosages of rituximab for adults with immune thrombocytopenia: a systematic review and Meta-Analysis, BioMed Res. Int. 2021 (2021), 9992086.
[35]E. Lucchini, F. Zaja, J. Bussel, Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019? Haematologica 104 (2019) 1124–1135.
[36] A. Fanouriakis, N. Tziolos, G. Bertsias, D.T. Boumpas, Update omicronn the diagnosis and management of systemic lupus erythematosus, Ann. Rheum. Dis. 80(2021) 14–25.
[37] L.M. Wise, W. Stohl, Belimumab and rituximab in systemic lupus erythematosus:a tale of two b Cell-Targeting agents, Front. Med. 7 (2020) 303.
[38] M. Mahevas, M. Michel, B. Vingert, J. Moroch, D. Boutboul, S. Audia, et al.,Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab, J. Autoimmun.62 (2015) 22–30.
[39] M. Mahevas, I. Azzaoui, E. Crickx, F. Canoui-Poitrine, D. Gobert, L. Languille, et al., Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia:results from a prospective phase 2b trial, Haematologica 106 (2021) 2449–2457.
[40] M. Pyzik, K. Sand, J.J. Hubbard, J.T. Andersen, I. Sandlie, R.S. Blumberg, The neonatal fc receptor (FcRn): a misnomer? Front. Immunol. 10 (2019) 1540.
[42] T. Robak, M. Kazmierczak, I. Jarque, V. Musteata, J. Trelinski, N. Cooper, et al.,Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia, Blood Adv 4 (2020) 4136–4146.
[43] A. Mocsai, J. Ruland, V.L. Tybulewicz, The SYK tyrosine kinase: a crucial player in diverse biological functions, Nat. Rev. Immunol. 10 (2010) 387–402.
[44] N.T. Connell, N. Berliner, Fostamatinib for the treatment of chronic immune thrombocytopenia, Blood 133 (2019) 2027–2030.
[45] D.J. Kuter, The biology of thrombopoietin and thrombopoietin receptor agonists,
Int. J. Hematol. 98 (2013) 10–23.
[47] P. Patwardhan, A. Landsteiner, L.S. Lal, L. Geevarghese, L. Le, S. Nandal, et al.,Eltrombopag treatment of patients with secondary immune thrombocytopenia:retrospective EHR analysis, Ann. Hematol. 101 (2022) 11–19.
[48] D. Provan, J.W. Semple, Recent advances in the mechanisms and treatment of immune thrombocytopenia, EBioMedicine 76 (2022), 103820。
[49] S. Panzer, I. Pabinger, Is oral all-trans retinoic acid plus danazol a refinement of second-line therapy for primary immune thrombocytopenia in adults? Lancet Haematol 4 (2017) e457–e458.
[50] F.E. Feng, R. Feng, M. Wang, J.M. Zhang, H. Jiang, Q. Jiang, et al., Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label,phase 2 trial, Lancet Haematol 4 (2017) e487–e496.
[51] Y.S. Ahn, R. Rocha, R. Mylvaganam, R. Garcia, R. Duncan, W.J. Harrington, Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women, Ann. Intern. Med. 111 (1989) 723–729.
[52] P.M. Baroni, P.R. Lev, A.C. Glembotsky, O.C. Marin, G. Gomez, V. Collado, et al.,Pathogenic mechanisms contributing to thrombocytopenia in patients with systemic lupus erythematosus, Platelets 33 (2022) 743–754.
[53] N. Revilla, J. Corral, A. Minano, M.E. Mingot-Castellano, R.M. Campos,F. Velasco, et al., Multirefractory primary immune thrombocytopenia; Targeting the decreased sialic acid content, Platelets 30 (2019) 743–751.
[55] ] R. Stasi, A. Sarpatwari, J.B. Segal, J. Osborn, M.L. Evangelista, N. Cooper, et al.,Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review, Blood 113 (2009) 1231–1240.
[56] M.C. Wu, J.Y. Huang, H.H. Chen, J.C. Wei, Effect of early eradication therapy on systemic lupus erythematosus risk in patients with Helicobacter pylori infection: a nationwide population-based cohort study, Lupus 29 (2020) 751–760.
[57]A. Remiker, C. Neunert, Splenectomy for immune thrombocytopenia: the evolution and preservation of treatment, Haematologica 105 (2020) 2507–2509.